Published in Curr Pharm Des on January 01, 2010
Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents. Pharmacol Ther (2010) 1.12
Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PLoS One (2012) 1.00
Apolipoprotein A-I and A-I mimetic peptides: a role in atherosclerosis. J Inflamm Res (2011) 1.00
Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis. J Med Chem (2013) 0.98
Apolipoprotein A-I attenuates palmitate-mediated NF-κB activation by reducing Toll-like receptor-4 recruitment into lipid rafts. PLoS One (2012) 0.93
HDL and cognition in neurodegenerative disorders. Neurobiol Dis (2014) 0.84
RISK and SAFE signaling pathway involvement in apolipoprotein A-I-induced cardioprotection. PLoS One (2014) 0.79
ATP Synthase β-Chain Overexpression in SR-BI Knockout Mice Increases HDL Uptake and Reduces Plasma HDL Level. Int J Endocrinol (2014) 0.77
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA (2003) 10.55
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation (1989) 9.97
Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A (1994) 3.24
Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA (2007) 3.12
Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest (1991) 3.07
Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation (2008) 2.98
Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation (2002) 2.91
Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation (2004) 2.62
Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res (2008) 2.51
Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol (2008) 2.41
Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol (2005) 2.33
Clusterin. Int J Biochem Cell Biol (2002) 2.30
Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res (2008) 2.28
Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res (2008) 2.27
Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res (2000) 2.22
Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res (2001) 2.11
Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ Res (2005) 2.06
D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2005) 1.99
Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res (2007) 1.96
Update on strategies to increase HDL quantity and function. Nat Rev Cardiol (2009) 1.94
The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J Biol Chem (2009) 1.92
Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem (1985) 1.89
Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med (1999) 1.80
HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol (2001) 1.74
Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res (2003) 1.68
Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res (2007) 1.65
A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. J Biol Chem (1990) 1.60
A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res (2001) 1.53
L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation (2003) 1.53
The apolipoprotein multigene family: biosynthesis, structure, structure-function relationships, and evolution. J Lipid Res (1988) 1.50
Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest (1997) 1.45
Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J Biol Chem (2008) 1.41
Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol (2009) 1.40
Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties. J Lipid Res (2008) 1.39
Interactions of synthetic peptide analogs of the class A amphipathic helix with lipids. Evidence for the snorkel hypothesis. J Biol Chem (1994) 1.39
A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids. J Lipid Res (2009) 1.37
A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res (2010) 1.36
Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation (2004) 1.35
Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1. J Lipid Res (2005) 1.30
Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. J Clin Invest (1994) 1.26
Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry (1995) 1.25
The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins. Biochemistry (2007) 1.24
Atheroprotective effects of HDL: beyond reverse cholesterol transport. Curr Drug Targets (2008) 1.24
D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation (2004) 1.20
Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties. Arterioscler Thromb (1992) 1.19
The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler Thromb Vasc Biol (2009) 1.19
Effect of end group blockage on the properties of a class A amphipathic helical peptide. Proteins (1993) 1.19
Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall. J Lipid Res (2008) 1.18
An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide. J Lipid Res (2009) 1.16
ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers. J Biol Chem (2006) 1.16
Aromatic residue position on the nonpolar face of class a amphipathic helical peptides determines biological activity. J Biol Chem (2004) 1.15
Apolipoprotein E mimetic Peptide dramatically lowers plasma cholesterol and restores endothelial function in watanabe heritable hyperlipidemic rabbits. Circulation (2005) 1.14
Studies of synthetic peptide analogs of the amphipathic helix. Correlation of structure with function. J Biol Chem (1985) 1.13
Identification of an apolipoprotein A-I structural element that mediates cellular cholesterol efflux and stabilizes ATP binding cassette transporter A1. J Biol Chem (2004) 1.13
An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2005) 1.12
HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease. J Lipid Res (1996) 1.11
The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry (2000) 1.10
Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. J Lipid Res (2003) 1.09
Serum amyloid A promotes ABCA1-dependent and ABCA1-independent lipid efflux from cells. Biochem Biophys Res Commun (2004) 1.08
Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats. Am J Physiol Heart Circ Physiol (2009) 1.07
Apoprotein A-I mimetic peptides and their potential anti-atherogenic mechanisms of action. Curr Opin Lipidol (2009) 1.04
Association of a model class A (apolipoprotein) amphipathic alpha helical peptide with lipid: high resolution NMR studies of peptide.lipid discoidal complexes. J Biol Chem (2006) 1.03
Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice. Atherosclerosis (2003) 1.03
Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice. Circ Res (2005) 1.03
An apolipoprotein A-I mimetic dose-dependently increases the formation of prebeta1 HDL in human plasma. J Lipid Res (2007) 1.02
Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH(2). Atherosclerosis (2009) 1.02
The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis. Trends Cardiovasc Med (2008) 0.99
Peptides derived from serum amyloid A prevent, and reverse, aortic lipid lesions in apoE-/- mice. J Lipid Res (2005) 0.96
Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo. J Lipid Res (2001) 0.91
Studies of synthetic peptide analogs of the amphipathic helix. Effect of charge distribution, hydrophobicity, and secondary structure on lipid association and lecithin:cholesterol acyltransferase activation. J Biol Chem (1987) 0.90
An apolipoprotein E synthetic peptide targets to lipoproteins in plasma and mediates both cellular lipoprotein interactions in vitro and acute clearance of cholesterol-rich lipoproteins in vivo. J Clin Invest (1998) 0.88
Macrophage cholesterol efflux and the active domains of serum amyloid A 2.1. J Lipid Res (2003) 0.88
Paraoxonase 1 interactions with HDL, antioxidants and macrophages regulate atherogenesis - a protective role for HDL phospholipids. Adv Exp Med Biol (2010) 0.82
Model class A and class L peptides increase the production of apoA-I-containing lipoproteins in HepG2 cells. J Lipid Res (2004) 0.79
Atherosclerosis and vascular disease: effects of peptide mimetics of apolipoproteins. Curr Pharm Biotechnol (2006) 0.79
Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem (1994) 2.66
Nucleotide sequence and structure of the human apolipoprotein E gene. Proc Natl Acad Sci U S A (1985) 2.16
Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice. J Biol Chem (1999) 1.64
Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem (1998) 1.45
Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. J Biol Chem (1995) 1.29
Isoform-specific effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J Neurosci (1998) 1.17
Apolipoprotein E and apolipoprotein E receptors modulate A beta-induced glial neuroinflammatory responses. Neurochem Int (2001) 1.13
Two copies of the human apolipoprotein C-I gene are linked closely to the apolipoprotein E gene. J Biol Chem (1988) 1.11
Apolipoprotein E receptors mediate the effects of beta-amyloid on astrocyte cultures. J Biol Chem (2000) 1.06
Association of human, rat, and rabbit apolipoprotein E with beta-amyloid. J Neurosci Res (1997) 1.06
Identification and characterization of transcriptional regulatory regions associated with expression of the human apolipoprotein E gene. J Biol Chem (1988) 0.99
Natural killer T cells in lipoprotein metabolism and atherosclerosis. Thromb Haemost (2011) 0.91
SAA-only HDL formed during the acute phase response in apoA-I+/+ and apoA-I-/- mice. J Lipid Res (1999) 0.89
SDS-stable complex formation between native apolipoprotein E3 and beta-amyloid peptides. Biochemistry (2000) 0.88
Inhibition of apolipoprotein E degradation in a post-Golgi compartment by a cysteine protease inhibitor. J Biol Chem (1993) 0.86
Post-translational regulation of macrophage apoprotein E production. J Biol Chem (1992) 0.85
The influence of acute phase proteins on murine atherosclerosis. Curr Drug Targets (2007) 0.84
Influence of dietary lipids on hepatic mRNA levels of proteins regulating plasma lipoproteins in baboons with high and low levels of large high density lipoproteins. J Lipid Res (1991) 0.80
The effect of tosyl lysine chloromethyl ketone on the activity of uridine diphosphoglucose pyrophosphorylase of the cellular slime mold Dictyostelium discoideum. Biochem Biophys Res Commun (1977) 0.78
The charge polymorphism of rat apoprotein E. J Biol Chem (1986) 0.78
Lipoprotein association of human apolipoprotein E/A-I chimeras. Expression in transfected hepatoma cells. J Biol Chem (1996) 0.77
Expression of the human apolipoprotein E gene in cultured mammalian cells. J Biol Chem (1986) 0.77
Relationships of plasma and hepatic variables with rates of plasma low-density lipoprotein apolipoprotein B metabolism in baboons fed low- and high-fat diets. Metabolism (1995) 0.76
Human plasma lipoproteins regulate apolipoprotein E secretion from a post-Golgi compartment. J Biol Chem (1992) 0.76
Effect of dietary lipids on plasma activity and hepatic mRNA levels of cholesteryl ester transfer protein in high- and low-responding baboons (Papio species). Metabolism (1994) 0.76
Processing of rat liver apoprotein E primary translation product. J Lipid Res (1984) 0.76
Characterization of an upstream regulatory sequence and its binding protein in the mouse apolipoprotein E gene. Biochim Biophys Acta (1995) 0.75
Metabolic mechanisms for responses to dietary cholesterol and fat in high and low LDL responding baboons (Papio sp.). J Lipid Res (1994) 0.75
Cloning and expression of the human apolipoprotein E gene. Methods Enzymol (1986) 0.75
Peptide model of a highly conserved, N-terminal domain of apolipoprotein E is able to modulate lipoprotein binding to a member of the class A scavenger receptor family. J Lipid Res (1999) 0.75